What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of Genmab A/S in a research note issued to investors on Friday, August 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.34 per share for the quarter, up from their prior forecast of $0.33. HC Wainwright currently has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.75 EPS and FY2026 earnings at $2.38 EPS.

GMAB has been the subject of a number of other research reports. Truist Financial upped their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Monday, July 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.60.

Genmab A/S Stock Up 1.4%

GMAB opened at $23.31 on Monday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $27.94. The company has a fifty day simple moving average of $21.80 and a 200 day simple moving average of $20.93. The stock has a market cap of $14.95 billion, a P/E ratio of 11.71, a P/E/G ratio of 6.85 and a beta of 0.95.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the business. Headlands Technologies LLC boosted its stake in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after buying an additional 1,464 shares during the last quarter. CWM LLC boosted its stake in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after buying an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after buying an additional 1,070 shares during the last quarter. AlphaCore Capital LLC acquired a new position in shares of Genmab A/S during the 2nd quarter worth about $44,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after buying an additional 1,174 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.